Hiroki Komatsuda, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2024 | 2891 | 0.880 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 1 | 2023 | 9 | 0.870 |
Why?
|
| Genes, Homeobox | 1 | 2022 | 284 | 0.770 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 2000 | 0.290 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2024 | 607 | 0.280 |
Why?
|
| Cancer Vaccines | 3 | 2024 | 1048 | 0.280 |
Why?
|
| Cutaneous Fistula | 1 | 2022 | 80 | 0.200 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2024 | 288 | 0.190 |
Why?
|
| Pharyngeal Diseases | 1 | 2022 | 136 | 0.190 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2024 | 824 | 0.190 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 306 | 0.180 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 302 | 0.170 |
Why?
|
| Epitopes | 2 | 2023 | 2501 | 0.170 |
Why?
|
| Mucositis | 1 | 2020 | 108 | 0.170 |
Why?
|
| Maxillary Sinus | 1 | 2020 | 180 | 0.160 |
Why?
|
| Immunotherapy | 6 | 2024 | 4626 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2021 | 369 | 0.160 |
Why?
|
| Neutropenia | 1 | 2023 | 885 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 1412 | 0.160 |
Why?
|
| Laryngeal Neoplasms | 1 | 2022 | 515 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2022 | 1248 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2022 | 1365 | 0.140 |
Why?
|
| Rhinitis | 1 | 2024 | 746 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 1342 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2024 | 2008 | 0.130 |
Why?
|
| Antigen Presentation | 1 | 2021 | 1247 | 0.130 |
Why?
|
| Cisplatin | 1 | 2021 | 1643 | 0.130 |
Why?
|
| Sinusitis | 1 | 2024 | 991 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 2630 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1059 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2022 | 4123 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2022 | 2413 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 4523 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2024 | 4299 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2335 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 10069 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2024 | 1074 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 4030 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 3812 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18094 | 0.060 |
Why?
|
| Vaccines, Subunit | 1 | 2024 | 162 | 0.060 |
Why?
|
| Neoplasms | 2 | 2022 | 22023 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2023 | 229 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 16878 | 0.050 |
Why?
|
| Humans | 14 | 2024 | 759098 | 0.050 |
Why?
|
| Mice | 6 | 2024 | 80993 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2022 | 321 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2022 | 257 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2024 | 80125 | 0.040 |
Why?
|
| Laryngectomy | 1 | 2022 | 244 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2024 | 568 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 172 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 626 | 0.040 |
Why?
|
| Nutritional Support | 1 | 2020 | 174 | 0.040 |
Why?
|
| Nasal Polyps | 1 | 2024 | 396 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2023 | 1716 | 0.030 |
Why?
|
| Animals | 6 | 2024 | 167531 | 0.030 |
Why?
|
| Aged | 5 | 2024 | 168615 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 2192 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6132 | 0.030 |
Why?
|
| Biopsy | 1 | 2024 | 6770 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 4526 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 6814 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4362 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 2925 | 0.020 |
Why?
|
| Peptides | 1 | 2022 | 4325 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 11125 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2024 | 9245 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 58864 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 219628 | 0.020 |
Why?
|
| Female | 5 | 2024 | 390174 | 0.020 |
Why?
|
| Cell Line | 1 | 2021 | 15638 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 21892 | 0.020 |
Why?
|
| Adult | 3 | 2024 | 219353 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9271 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10427 | 0.020 |
Why?
|
| Male | 4 | 2024 | 358602 | 0.020 |
Why?
|
| Prognosis | 1 | 2024 | 29559 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2022 | 26099 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5247 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 20461 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2022 | 15662 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13625 | 0.010 |
Why?
|
| Child | 1 | 2022 | 79604 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 87551 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 64867 | 0.010 |
Why?
|